When.com Web Search

  1. Ads

    related to: macular degeneration treatment eye drops

Search results

  1. Results From The WOW.Com Content Network
  2. Pegaptanib - Wikipedia

    en.wikipedia.org/wiki/Pegaptanib

    Pegaptanib [2] sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). [3] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States.

  3. Intravitreal injection - Wikipedia

    en.wikipedia.org/wiki/Intravitreal_injection

    Age-related macular degeneration (AMD)/ Macular Degeneration: An eye disorder that slowly destroys sharp, central vision [11] [12] Uveitis: Swelling and inflammation within the eyeball [1] Retinal vein occlusion: A blockage of the veins that carry blood away from the retina, the back part of your eye, and out of the eye [1]

  4. FDA Approves Biosimilars for Macular Degeneration Treatment - AOL

    www.aol.com/fda-approves-biosimilars-macular...

    The FDA approved two interchangeable biosimilars to treat macular degeneration. The biosimilars work the same way as Eylea which prevents abnormal blood vessel growth in the eye and helps preserve ...

  5. Aflibercept - Wikipedia

    en.wikipedia.org/wiki/Aflibercept

    Common adverse effects of the eye formulation include conjunctival hemorrhage, eye pain, cataract, vitreous detachment, floaters, and ocular hypertension. [11]Aflibercept (Zaltrap) has adverse effects typical of anti-cancer drugs, such as reduced blood cell count (leukopenia, neutropenia, thrombocytopenia), gastrointestinal disorders like diarrhea and abdominal pain, and fatigue.

  6. Faricimab - Wikipedia

    en.wikipedia.org/wiki/Faricimab

    On 21 July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vabysmo, intended for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME ...

  7. Intravitreal administration - Wikipedia

    en.wikipedia.org/wiki/Intravitreal_administration

    Severe inflammation can cause permanent damage to the eye. The risk of inflammation varies based on the specific drug being administered. One clinical trial of ranibizumab for age-related macular degeneration administered intravitreally reported intraocular inflammation rates between 1.4% and 2.9%.